Vivek Rajwanshi

Vivek Rajwanshi has extensive work experience in the field of chemistry and biochemistry. Vivek started their career at the University of Copenhagen as a Postdoctoral Research Associate, where they conducted research on the design and synthesis of Locked Nucleic Acids (LNA) and their binding affinities with RNA and DNA. Vivek also performed novel syntheses of thymine-based LNA and cytosine-based bicyclonucleoside monomers.

After their time in Copenhagen, Rajwanshi worked as a Postdoctoral Research Associate at Brigham Young University, where they synthesized enediynes and nucleoside derivatives as potential anti-viral agents. Vivek also synthesized a series of nucleosides as potential anti-viral inhibitors.

Rajwanshi then joined various companies in the pharmaceutical industry, including Biota Inc., Genelabs Technologies, and Alios BioPharma. At these companies, they held roles of increasing seniority, including Scientist II, Scientist III, Senior Scientist, and Principal Scientist. Their work in these positions focused on medicinal chemistry, with a specific emphasis on nucleosides and oligonucleotides.

In 2018, Rajwanshi joined Aligos Therapeutics as a Director of Oligonucleotide Chemistry. Vivek was later promoted to Senior Director in 2021. In these roles, they are responsible for leading and directing the development of oligonucleotide-based therapies.

Overall, Vivek Rajwanshi has a wealth of experience in the field of chemistry and has made significant contributions to the development of nucleoside and oligonucleotide-based therapies throughout their career.

Vivek Rajwanshi completed their Ph.D. in Organic Chemistry at Delhi University from 1992 to 1997. Following this, they pursued a Post Doctoral Fellowship at Københavns Universitet - University of Copenhagen from 1997 to 2000, under the guidance of Professor Jesper Wengel, focusing on the synthesis of Locked Nucleic acids (LNA's) and their properties. From 2000 to 2001, Vivek Rajwanshi continued their post-doctoral studies in Medicinal Chemistry at Brigham Young University. Lastly, from 2001 to 2002, they joined The Scripps Research Institute as a Postdoc, specializing in the study of Nucleosides, nucleotides, and Nucleic acids.